ストックスクリーナーアプリを入手
5.325
2.40%
0.125
アフターアワーズ：
5.27
-0.055
-1.03%
Pavmed Inc (PAVM) 最新ニュース
St. Joseph's Health Now Offers Pluvicto For Advanced Prostate Cancer - AOL.com
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
PAVmed reports Q2 progress with Veris, Lucid, a... - Pluang
PAVmed (PAVM) Q2 2026 Earnings Call Transcript - The Globe and Mail
PAVmed Inc (PAVM) (Q2 2026) Earnings Call Highlights: Narrowing - GuruFocus
Pavmed Stock Price Forecast. Should You Buy PAVM? - StockInvest.us
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
PAVM Q2 FY2026 earnings call - finance.biggo.com
PAVM Looks 288.7% Overvalued on GF Value™ - GuruFocus
Is PAVmed Inc (PAVM) Overvalued After Q2 Earnings Miss? EPS at -$0.55, Revenue at $0.05M; GF Score: 32/100 - GuruFocus
Form 8K PAVmed Inc For: 14 August By Investing.com - Investing.com Nigeria
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com Australia
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVM: Q2 saw operational progress, positive clinical results, and improved financial positioning - TradingView
PAVM: Net loss narrowed and operational progress advanced, with regulatory milestones on track - TradingView
PAVmed Q2 2026 Earnings Call: Complete Transcript - Benzinga
Q2 2026 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
PAVmed Q2 2026 Earnings Call Transcript - MarketBeat
PAVmed Inc. (PAVM) investor discloses 8.8% stake and trust holdings - Stock Titan
PAVmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
PAVmed (PAVM) Releases Q2 2026 Earnings: Revenue Miss and Continued Losses - Quiver Quantitative
PAVmed Inc. 2026: Revenue $33K, EPS ($0.87) — 10-Q Summary - TradingView
PAVmed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
PAVmed Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
PAVmed Inc (NASDAQ: PAVM) Share Price, PAVM Stock News, PAVM Share Price & Updates - Kalkine
PAVM Q2'26 Earnings: revenue estimate is 48.00K USD - TradingView
Lucid Diagnostics Secures Commercial Coverage - Moomoo
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test - Morningstar
PAVmed unit Lucid Diagnostics wins Concert commercial coverage policy for EsoGuard test - Bitget
P&F Products & Features GmbH Announces Acquisition of AVVie GmbH - AOL.com
Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria - Stock Titan
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Morningstar
Academic Orthopaedic Consortium Launches POST™, the First National Digital Platform Connecting MedTech, Pharma, and Academic Orthopaedic Departments - AOL.com
Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings - Stock Titan
Weekly Recap: Q2 2026 earnings call and EsoGuard/EsoCheck sales - TradingView
PAVmed Inc. (PAVM) Climbs 4.42% to $5.24 as Bullish Momentum BuildsGap Up Stocks - dars.gov.et
PAVmed CEO to update operations; CFO to discuss Q2 financial results Aug. 14 - Stock Titan
PAVmed to Host Business Update Conference Call on August 14 - Intellectia AI
PAVMED Q1 2026 Earnings: EPS Shock Sinks Shares as Revenue Remains UnreportedEarnings Surprise Stocks - dars.gov.et
PAVmed Inc (PAVM) Cash Flow - TradingKey
Lucid Diagnostics Inc (LUCD) Institutional Confidence - TradingKey
Lucid Diagnostics Inc (LUCD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PAVmed Inc (PAVM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PAVmed Inc (PAVM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PAVmed Inc (PAVM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PAVmed Inc (PAVM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PAVmed Inc (PAVM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
PAVM|PAVmed Inc|Price:4.860|Chg%:-0.180 - tradingkey.com
PAVmed Inc. Revenue Breakdown – NASDAQ:PAVM - TradingView
PAVM|PAVmed Inc|Price:4.740|Chg%:+0.130 - TradingKey
PAVmed Inc (PAVM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PAVmed Inc (PAVM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
PAVM Q1 2026 Earnings: EPS Falls Far Short of Estimates Amid Operational ChallengesTech Earnings Analysis - po-news-eg.net
PAVmed Q1 2026 Earnings: Hefty EPS Miss Masks Optimism as Stock ClimbsLow Growth Earnings - dars.gov.et
PAVmed Inc. (PAVM) Posts Modest Gain, Holding Above Key SupportDark Pool Sentiment - dars.gov.et
Price to sales forward of PAVmed Inc. – NASDAQ:PAVM - TradingView
Price to book forward of PAVmed Inc. – NASDAQ:PAVM - TradingView
2.43%
大文字化:
|
ボリューム (24 時間):